UNSPSC 51182406: Alendronic acid or alendronate sodium

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C4H13NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1J18R4W8P, chemically known as 4-amino-1-hydroxybutylidene-1,1-bis(phosphonic acid) but generally known as alendronate, which bears US NIH Compound Identifier 2088. Alendronate comes in forms hydrate, sodium, and trihydrate. European Medicines Agency schedules Alendronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05307MIG.

UNSPSC 51182406 Alendronic acid or alendronate sodium is a Commodity code that shows little relevant recent activity under state and local procurement. The three opportunities tagged with this pharmaceutical code in the recent-opportunities block—athletic training services for Tucson Fire and Police, general medical aid supplies for Tampa Fire Rescue, and sodium hypochlorite and sulfuric acid for Orange County water treatment—bear no meaningful connection to alendronate sodium, a bisphosphonate medication used to treat osteoporosis. The mismatch between the code's nominal scope (a specific pharmaceutical active ingredient) and the actual work being solicited suggests either systematic tagging error or that the code does not reflect current state and local purchasing patterns for this drug class.

State and local procurement of pharmaceutical products, when it occurs, typically flows through health department contracts, employee health plan procurement (handled by benefits administrators or pharmacy benefit managers), or institutional pharmacy purchasing at public hospitals and clinics rather than through standalone solicitations tagged to specific drug codes. Without evidence of recent dedicated solicitations for alendronate sodium or related bisphosphonate medications by state departments, counties, cities, school districts, or transit authorities, this code presents no actionable signal for business development targeting state and local markets. Monitor for future RFPs or cooperative purchasing agreements from state pharmacy programs or large municipal health systems, but treat current activity under this code as inactive for state and local purposes.